The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta‐analysis
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,361
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1113697 · Cited by 983
Linkins, L.-A., Choi, P. T., & Douketis, J. D. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-11-200312020-00007 · Cited by 764
Carrier, M., Le Gal, G., Wells, P. S., & Rodger, M. A. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-9-201005040-00008 · Cited by 473
Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran
Schulman, S., Wåhlander, K., Lundström, T., Clason, S. B., & Eriksson, H. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030104 · Cited by 454
Agnelli, G., Gallus, A., Goldhaber, S. Z., Haas, S., Huisman, M. V., Hull, R. D., Kakkar, A. K., Misselwitz, F., & Schellong, S. (2007) · Circulation · doi:10.1161/circulationaha.106.668020 · Cited by 337
Self-citationIdraparinux versus Standard Therapy for Venous Thromboembolic Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa064247 · Cited by 335
Fiessinger, J.-N., Huisman, M. V., Davidson, B. L., Bounameaux, H., Francis, C. W., Eriksson, H., Lundström, T., Berkowitz, S. D., Nyström, P., Thorsén, M., et al. (2005) · JAMA · doi:10.1001/jama.293.6.681 · Cited by 295
Self-citationManagement and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
Majeed, A., Hwang, H.-G., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Wallentin, L., Brueckmann, M., Fraessdorf, M., Yusuf, S., & Schulman, S. (2013) · Circulation · doi:10.1161/circulationaha.113.002332 · Cited by 277
Douketis, J. D., Foster, G. A., Crowther, M. A., Prins, M. H., & Ginsberg, J. S. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.22.3431 · Cited by 269
BULLER, H., DEITCHMAN, D., PRINS, M., & SEGERS, A. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03054.x · Cited by 252
New oral anticoagulant drugs in cardiovascular disease
Lip, G., Peter, K., & Ahrens, I. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-05-0327 · Cited by 227
Castellucci, L. A., Cameron, C., Le Gal, G., Rodger, M. A., Coyle, D., Wells, P. S., Clifford, T., Gandara, E., Wells, G., & Carrier, M. (2013) · BMJ · doi:10.1136/bmj.f5133 · Cited by 193
Diagnostic management of acute deep vein thrombosis and pulmonary embolism
Huisman, M. V., & Klok, F. A. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12124 · Cited by 176
Self-citationFox, B. D., Kahn, S. R., Langleben, D., Eisenberg, M. J., & Shimony, A. (2012) · BMJ · doi:10.1136/bmj.e7498 · Cited by 138
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Middeldorp, S., Prins, M. H., & Hutten, B. A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001367.pub3 · Cited by 133
Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran
Weitz, J. I., Quinlan, D. J., & Eikelboom, J. W. (2012) · Circulation · doi:10.1161/circulationaha.112.123224 · Cited by 109
Schulman, S., Kakkar, A. K., Schellong, S., Goldhaber, S. Z., Henry, E., Mismetti, P., Christiansen, A. V., Schnee, J. M., & Kearon, C. (2011) · Blood · doi:10.1182/blood.v118.21.205.205 · Cited by 95
Dale, B. J., Eikelboom, J. W., Weitz, J. I., Young, E., Paikin, J. S., Coppens, M., Whitlock, R. P., Connolly, S. J., Ginsberg, J. S., & Hirsh, J. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0857-9 · Cited by 71
Rivaroxaban – an oral, direct Factor Xa inhibitor – lessons from a broad clinical study programme
Haas, S. K. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01230.x · Cited by 59
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Hutten, B. A., & Prins, M. H. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001367.pub2 · Cited by 58
[Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
Sprynger, M. G. (2013) · PubMed · Cited by 28
Lega, J., Mismetti, P., Cucherat, M., Fassier, T., Bertoletti, L., Chapelle, C., & Laporte, S. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12294 · Cited by 21
O'Neil, W. J., Welner, S. A., & Lip, G. Y. H. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-10-0715 · Cited by 20
Research works printed but not linked: 3
- Eriksson, 2003, A randomized, controlled, dose‐guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I, J Thromb Haemost, 1, 41, 10.1046/j.1538-7836.2003.00034.x · doi:10.1046/j.1538-7836.2003.00034.x
- Wahlander, 2002, Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis, Thromb Res, 107, 93, 10.1016/S0049-3848(02)00259-1 · doi:10.1016/s0049-3848(02)00259-1
- Agnelli, 2013, Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, 799, 10.1056/NEJMoa1302507 · DOI · Paper page
Cited by
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000950 · Cited by 5,784
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Self-citation
Metadata
- Authors
- van der Hulle, T., Kooiman, J., den Exter, P. L., Dekkers, O. M., Klok, F. A., & Huisman, M. V.
- Venue
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 12
- Issue
- 3
- Pages
- 320-328
- ISSN
- 1538-7836 (ISSN-L)
- OpenAlex
- W2113561246
- Cited by
- 536
- References
- 31
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 3172 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.